US 12,170,141 B2
Method and system for evaluating efficacy of a therapeutic intervention
Chi Shang Tai, Singapore (SG); and Yayun Ren, Singapore (SG)
Assigned to Histoindex Pte Ltd., Singapore (SG)
Appl. No. 17/789,657
Filed by Histoindex Pte Ltd, Singapore (SG)
PCT Filed Jan. 7, 2021, PCT No. PCT/SG2021/050007
§ 371(c)(1), (2) Date Jun. 28, 2022,
PCT Pub. No. WO2021/141537, PCT Pub. Date Jul. 15, 2021.
Claims priority of provisional application 62/958,520, filed on Jan. 8, 2020.
Prior Publication US 2023/0033034 A1, Feb. 2, 2023
Int. Cl. G16H 30/40 (2018.01); G01N 21/64 (2006.01); G06T 7/00 (2017.01); G16H 50/30 (2018.01)
CPC G16H 30/40 (2018.01) [G01N 21/6458 (2013.01); G06T 7/0016 (2013.01); G16H 50/30 (2018.01); G06T 2207/10056 (2013.01); G06T 2207/30024 (2013.01); G06T 2207/30056 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method for evaluating efficacy of a therapeutic intervention, the method comprising:
obtaining, from each of paired liver biopsy samples of a subject comprising a first sample prior to the therapeutic intervention and a second sample after the therapeutic intervention, a first set of image data indicative of a first histopathological feature and a second set of image data indicative of a second histopathological feature;
for each of the first and second samples:
quantifying the second histopathological feature;
overlapping the first and second sets of image data based on a common reference frame; and
quantifying the first histopathological feature present in an overlapping area of the first and second sets of image data; and
determining the efficacy of the therapeutic intervention based on a comparison of the quantified second histopathological feature between the first and second samples and/or a comparison of the quantified first histopathological feature in the overlapping area between the first and second samples,
wherein the first and second pathological features comprise features selected from the group consisting of fibrosis, inflammation, ballooning and steatosis.